Immunosuppressants
Mostrando 25-36 de 89 artigos, teses e dissertações.
-
25. Antibiotics produced by Streptomyces
Streptomyces is a genus of Gram-positive bacteria that grows in various environments, and its shape resembles filamentous fungi. The morphological differentiation of Streptomyces involves the formation of a layer of hyphae that can differentiate into a chain of spores. The most interesting property of Streptomyces is the ability to produce bioactive secondar
Braz J Infect Dis. Publicado em: 2012-10
-
26. Immunosuppressants: implications in Orthodontics
INTRODUCTION: There are medications capable of affecting bone metabolism and the rate of tooth movement. Among these medications are the immunosuppressants, which act by repressing the action of T lymphocytes, however they can cause bone loss and consequently lead to osteoporosis. Osteoporosis is a common complication following kidney, heart, liver or lung t
Dental Press Journal of Orthodontics. Publicado em: 2012-04
-
27. A proton nuclear magnetic resonance-based metabonomics study of metabolic profiling in immunoglobulin a nephropathy
OBJECTIVES: Immunoglobulin A nephropathy is the most common cause of chronic renal failure among primary glomerulonephritis patients. The ability to diagnose immunoglobulin A nephropathy remains poor. However, renal biopsy is an inconvenient, invasive, and painful examination, and no reliable biomarkers have been developed for use in routine patient evaluati
Clinics. Publicado em: 2012
-
28. Ensaios sobre a economia dos transplantes renais no Brasil : incentivos e eficiência
The thesis is about the economy of kidney transplants, focusing on the institutional mechanisms and incentives related to organ harvesting in Brazil, as well as the efficiency of the Brazilian states that perform such transplants. The essays investigated the effects and implications of the incentives structure on the number of organs (including kidney) harve
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 2012
-
29. O uso de imunossupressores e alterações menstruais em pacientes lúpicas / O uso de imunossupressores e alterações menstruais em pacientes lúpicas / The use of immunosuppressants and menstrual disorders in patients with lupus / The use of immunosuppressants and menstrual disorders in patients with lupus
BACKGROUND: The Systemic Lupus Erythematosus (SLE) is an autoimmune disease that affects mainly women, and studies have shown that the use of immunosuppressants (IS) during SLE treatment may affect ovarian function. OBJECTIVES: This study aimed at the determination of possible associations in various IS therapeutic schemes and disturb in the ovarian function
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 17/09/2009
-
30. O uso de imunossupressores e alterações menstruais em pacientes lúpicas / O uso de imunossupressores e alterações menstruais em pacientes lúpicas / The use of immunosuppressants and menstrual disorders in patients with lupus / The use of immunosuppressants and menstrual disorders in patients with lupus
BACKGROUND: The Systemic Lupus Erythematosus (SLE) is an autoimmune disease that affects mainly women, and studies have shown that the use of immunosuppressants (IS) during SLE treatment may affect ovarian function. OBJECTIVES: This study aimed at the determination of possible associations in various IS therapeutic schemes and disturb in the ovarian function
Publicado em: 2009
-
31. Experimental models of liver regeneration in growing animals. Histological and molecular studies, and evaluation of the effects of immunosuppressants / Modelos de regeneração hepática em animais em crescimento: estudos histológicos, moleculares e avaliação de efeitos de imunossupressores
INTRODUCTION: Partial liver transplantation has been performed in children with increasing frequency, and this emphasizes the importance of the studies of hepatic regeneration and the effects of immunosuppressive drugs on this phenomenon. Liver regeneration is controlled by the balance between cell proliferation and apoptosis (defined as a programmed cell de
Publicado em: 2007
-
32. In Vitro Interactions between Antifungals and Immunosuppressants against Aspergillus fumigatus Isolates from Transplant and Nontransplant Patients
We performed in vitro antifungal checkerboard testing on 12 Aspergillus fumigatus clinical isolates (6 transplant recipients and 6 nontransplant patients) with three antifungal agents (amphotericin B, voriconazole, and caspofungin) and three immunosuppressants (FK506, cyclosporine, and rapamycin). We were not able to detect a difference in calcineurin inhibi
American Society for Microbiology.
-
33. In Vitro Interactions between Antifungals and Immunosuppressants against Aspergillus fumigatus
The optimal treatment for invasive aspergillosis remains elusive, despite the increased efficacy of newer agents. The immunosuppressants cyclosporine (CY), tacrolimus (FK506), and sirolimus (formerly called rapamycin) exhibit in vitro and in vivo activity against Candida albicans, Cryptococcus neoformans, and Saccharomyces cerevisiae, including fungicidal sy
American Society for Microbiology.
-
34. Factors affecting colonization and dissemination of Candida albicans from the gastrointestinal tract of mice.
Male ICR Swiss mice (2 to 3 months old) were fed Candida albicans in their drinking water for 3 days, followed by no treatment, antibiotics in their drinking water (daily), or immunosuppressants given by intraperitoneal injection (two to three times weekly) over a 3- to 4-week period. The organs of animals were processed to determine the numbers of C. albica
-
35. Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands.
The peptidyl-prolyl isomerases FKBP12 and cyclophilin A (immunophilins) form complexes with the immunosuppressants FK506 and cyclosporin A that inhibit the phosphatase calcineurin. With the yeast two hybrid system, we detect complexes between FKBP12 and the calcineurin A catalytic subunit in both the presence and absence of FK506. Mutations in FKBP12 surface
-
36. Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
Since the introduction of infliximab to treat Crohn's disease, combination therapy with immunosuppressants has reduced immunogenicity, without impacting efficacy. The availability of novel anti‐TNF agents and potential combined toxicities question the risk/benefit of combination therapies.
BMJ Group.